GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LBT Innovations Ltd (ASX:LBT) » Definitions » Total Liabilities

LBT Innovations (ASX:LBT) Total Liabilities : A$5.57 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is LBT Innovations Total Liabilities?

LBT Innovations's Total Liabilities for the quarter that ended in Dec. 2023 was A$5.57 Mil.

LBT Innovations's quarterly Total Liabilities declined from Dec. 2022 (A$9.72 Mil) to Jun. 2023 (A$7.48 Mil) and declined from Jun. 2023 (A$7.48 Mil) to Dec. 2023 (A$5.57 Mil).

LBT Innovations's annual Total Liabilities declined from Jun. 2021 (A$10.81 Mil) to Jun. 2022 (A$10.19 Mil) and declined from Jun. 2022 (A$10.19 Mil) to Jun. 2023 (A$7.48 Mil).


LBT Innovations Total Liabilities Historical Data

The historical data trend for LBT Innovations's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LBT Innovations Total Liabilities Chart

LBT Innovations Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.61 9.65 10.81 10.19 7.48

LBT Innovations Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.31 10.19 9.72 7.48 5.57

LBT Innovations Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LBT Innovations's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.189+(2.193+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.856+0.237)
=7.48

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=7.37--0.105
=7.48

LBT Innovations's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.253+(1.337+2.065
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.918+0)
=5.57

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=8.125-2.552
=5.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LBT Innovations Total Liabilities Related Terms

Thank you for viewing the detailed overview of LBT Innovations's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


LBT Innovations (ASX:LBT) Business Description

Traded in Other Exchanges
N/A
Address
16 Anster Street, Adelaide, SA, AUS, 5000
LBT Innovations Ltd is a designer of advanced technology solutions for the medical industry. Its first product, MicroStreak, was a global first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation.

LBT Innovations (ASX:LBT) Headlines

No Headlines